456 related articles for article (PubMed ID: 33907401)
21. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
22. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
23. Extracellular vesicles derived from Trichinella spiralis prevent colitis by inhibiting M1 macrophage polarization.
Gao X; Yang Y; Liu X; Wang Y; Yang Y; Boireau P; Liu M; Bai X
Acta Trop; 2021 Jan; 213():105761. PubMed ID: 33221281
[TBL] [Abstract][Full Text] [Related]
24. Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.
Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1410-1420. PubMed ID: 36852791
[TBL] [Abstract][Full Text] [Related]
25. Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity.
Ortiz-Bonilla CJ; Uccello TP; Gerber SA; Lord EM; Messing EM; Lee YF
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328324
[TBL] [Abstract][Full Text] [Related]
26. Novel antitumor therapeutic strategy using CD4
Shin S; Jung I; Jung D; Kim CS; Kang SM; Ryu S; Choi SJ; Noh S; Jeong J; Lee BY; Park JK; Shin J; Cho H; Heo JI; Jeong Y; Choi SH; Lee SY; Baek MC; Yea K
Biomaterials; 2022 Oct; 289():121765. PubMed ID: 36067566
[TBL] [Abstract][Full Text] [Related]
27. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth.
Cao M; Yan H; Han X; Weng L; Wei Q; Sun X; Lu W; Wei Q; Ye J; Cai X; Hu C; Yin X; Cao P
J Immunother Cancer; 2019 Nov; 7(1):326. PubMed ID: 31775862
[TBL] [Abstract][Full Text] [Related]
28. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
30. A novel 3D heterotypic spheroid model for studying extracellular vesicle-mediated tumour and immune cell communication.
Sadovska L; Zandberga E; Sagini K; Jēkabsons K; Riekstiņa U; Kalniņa Z; Llorente A; Linē A
Biochem Biophys Res Commun; 2018 Jan; 495(2):1930-1935. PubMed ID: 29248729
[TBL] [Abstract][Full Text] [Related]
31. Immune Cell-Derived Extracellular Vesicles - New Strategies in Cancer Immunotherapy.
Yang P; Peng Y; Feng Y; Xu Z; Feng P; Cao J; Chen Y; Chen X; Cao X; Yang Y; Jie J
Front Immunol; 2021; 12():771551. PubMed ID: 34956197
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory Effects of Canine Adipose Tissue Mesenchymal Stem Cell-Derived Extracellular Vesicles on Stimulated CD4
Teshima T; Yuchi Y; Suzuki R; Matsumoto H; Koyama H
J Immunol Res; 2021; 2021():2993043. PubMed ID: 34447855
[TBL] [Abstract][Full Text] [Related]
33. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8
Liu C; Chikina M; Deshpande R; Menk AV; Wang T; Tabib T; Brunazzi EA; Vignali KM; Sun M; Stolz DB; Lafyatis RA; Chen W; Delgoffe GM; Workman CJ; Wendell SG; Vignali DAA
Immunity; 2019 Aug; 51(2):381-397.e6. PubMed ID: 31350177
[TBL] [Abstract][Full Text] [Related]
34. Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T-cells and tumour cells.
Del Vecchio F; Martinez-Rodriguez V; Schukking M; Cocks A; Broseghini E; Fabbri M
J Extracell Vesicles; 2021 Apr; 10(6):e12075. PubMed ID: 33815694
[TBL] [Abstract][Full Text] [Related]
35. Trophoblast-Derived Extracellular Vesicles Promote Preeclampsia by Regulating Macrophage Polarization.
Liu X; Fei H; Yang C; Wang J; Zhu X; Yang A; Shi Z; Jin X; Yang F; Wu D; Jiang L; Zhang S
Hypertension; 2022 Oct; 79(10):2274-2287. PubMed ID: 35993233
[TBL] [Abstract][Full Text] [Related]
36. Delivery of SIRT1 by cancer-associated adipocyte-derived extracellular vesicles regulates immune response and tumorigenesis of ovarian cancer cells.
Zheng Q; Du X; Zhang J; Liu Y; Dong W; Dai X; Gu D
Clin Transl Oncol; 2024 Jan; 26(1):190-203. PubMed ID: 37311988
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance.
Wang X; Ye X; Chen Y; Lin J
Int Immunopharmacol; 2023 Nov; 124(Pt A):110848. PubMed ID: 37633233
[TBL] [Abstract][Full Text] [Related]
38. Extracellular vesicular lncRNA FAL1 promotes hepatocellular carcinoma cell proliferation and invasion by inducing macrophage M2 polarization.
Lv S; Wang J; Li L
J Physiol Biochem; 2023 Aug; 79(3):669-682. PubMed ID: 37147492
[TBL] [Abstract][Full Text] [Related]
39. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
[TBL] [Abstract][Full Text] [Related]
40. Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
Graham R; Gazinska P; Zhang B; Khiabany A; Sinha S; Alaguthurai T; Flores-Borja F; Vicencio J; Beuron F; Roxanis I; Matkowski R; Liam-Or R; Tutt A; Ng T; Al-Jamal KT; Zhou Y; Irshad S
Front Immunol; 2023; 14():1204224. PubMed ID: 37441083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
